查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2014687

H1N1疫苗市場：2026-2032年全球市場預測（依產品類型、技術、劑型、年齡層、最終用戶及通路分類）

H1N1 Vaccines Market by Product Type, Technology, Dosage Form, Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，H1N1 疫苗市場價值將達到 183.2 億美元，到 2026 年將成長至 249.6 億美元，到 2032 年將達到 1623.2 億美元，複合年成長率為 36.56%。

主要市場統計數據
基準年 2025 183.2億美元
預計年份：2026年 249.6億美元
預測年份 2032 1623.2億美元
複合年成長率 (%) 36.56%

從臨床、生產、監管和分銷角度分析當前 H1N1 疫苗市場狀況，以進行策略決策。

本執行摘要概述了影響當前H1N1疫苗格局的關鍵策略、營運和監管因素。疫苗接種計劃、生產平台和採購政策與不斷變化的公共衛生重點和技術進步緊密交織，形成了一個複雜的環境，製造商、醫療系統和分銷合作夥伴必須密切合作。本概要提出了決策者在將研發投資、供應鏈韌性和商業策略與全球免疫宣傳活動的實際情況相結合時應考慮的核心主題。

確定將重塑 H1N1 疫苗的研發、生產和分銷的根本性結構變化，以創新和業務永續營運為驅動力。

在平台創新、供應鏈現代化和相關人員期望轉變的驅動下，H1N1疫苗領域正經歷著一場變革。重組抗原生產和細胞培養製造技術的進步正在挑戰傳統的以雞蛋培養為基礎的模式，改變了株更新週期，並實現了更靈活的生產力計畫。同時，低溫運輸監控、訂單管理和庫存預測的數位化正在提高分銷的可預測性，並提升整個價值鏈透明度的期望。

本分析探討了美國關稅政策如何改變 H1N1 疫苗市場相關人員的採購經濟、供應鏈設計和採購複雜性。

2025年美國關稅趨勢將對H1N1疫苗生態系統產生重大影響，具體體現在投入成本、供應商選擇和跨國生產策略等。關稅措施若增加進口零件（從專用試劑和一次性生物製程耗材到包裝材料和某些成品）的接收成本，將直接影響製造業的經濟效益。這些成本壓力將促使製造商重新評估籌資策略，並可能優先考慮國內供應商或在監管和品質框架合適的地區選擇近岸外包方案。因此，隨著供應鏈的重新檢驗，前置作業時間可能會發生變化，並可能出現過渡期的複雜性。

根據細分市場（包括產品類型、技術、最終用戶、通路、劑型和年齡層）解讀細微的需求，從而製定策略。

細分市場層面的趨勢揭示了不同的商業性和營運重點，這些重點應體現在產品組合和通路策略的發展中。根據產品類型，市場調查涵蓋去活化疫苗和減毒活病毒疫苗。去活化疫苗進一步細分為細胞培養型、雞胚培養型和重組型，並進行深入研究。減毒活病毒疫苗則進一步細分為雞胚培養型，並進行深入研究。這些產品差異會影響生產計劃、監管要求和臨床醫生的偏好。細胞培養型和重組型去活化疫苗具有適應性優勢，而雞胚培養型減毒活病毒疫苗則在特定應用項目中保持效用。

該評估旨在評估美洲、歐洲、中東和非洲以及亞太地區在法規、製造和採購方面的差異如何影響營運策略和夥伴關係。

區域趨勢造就了獨特的營運條件和政策環境，進而影響生產分配、分銷模式和監管互動。美洲地區擁有先進的生產能力、集中採購計畫和成熟的公共衛生基礎設施，這些優勢既支持新型疫苗的快速部署，也需要強力的商業性證據來確保其被納入處方集。歐洲、中東和非洲（EMEA）地區則兼具高度監管的市場、採購成熟度不一以及不斷變化的本地生產需求，因此需要靈活的監管策略和供應模式，以應對高容量醫療系統和資源受限的環境。

分析決定 H1N1 疫苗供應可靠性、監管靈活性和競爭優勢的企業層級優勢和策略能力。

H1N1疫苗領域的競爭地位取決於平台能力、生產規模、監管關係和夥伴關係網路等多面向因素。主要企業透過建立包含細胞培養和重組技術以及傳統雞蛋培養技術的多平台產品組合來發揮自身優勢，從而能夠將生產資源分配到最高效的地點，並降低供應中斷的風險。投資於填充和包裝能力以及第三方合作的企業可以減少瓶頸，並更好地滿足多樣化的分銷管道和劑型需求。

製造商、經銷商和公共衛生合作夥伴可以採取切實可行的、優先考慮的策略措施，以增強韌性並加快部署。

行業領導者應優先考慮一系列切實可行的舉措，使技術能力與市場和公共衛生需求相契合。首先，透過投資和合作開發細胞衍生和重組技術，擴大平台柔軟性，同時在存在臨床適應症的情況下，維持目標卵源性生產能力。這種方法能夠增強對抗原突變的適應能力，並降低對單一技術的依賴風險。其次，透過多元化的採購結構和合約條款，正式確立供應保障，以應對關稅和海關程序的波動，從而保護採購承諾並最大限度地減少供應中斷。

本文描述了一種多來源調查方法，該方法結合了相關人員訪談、監管審查和跨學科檢驗，以確保獲得實用可靠的見解。

本分析的調查方法透過結合與主要相關人員的對話、整合二手文獻以及跨領域專家檢驗，確保了研究結果的可靠性和可操作性。關鍵投入包括對生產經理、監管專家、採購負責人和分銷經理進行結構化訪談，以了解不同生產平台和分銷管道的營運實際情況。這些訪談重點在於生產限制、監管路徑、特定管道的劑量趨勢以及與診所、醫院和公共衛生中心相關的採購考慮。

確定策略挑戰和營運重點，以全面提高 H1N1 疫苗計劃的準備度、可靠性和公共衛生影響。

總而言之，目前的H1N1疫苗市場需要一種整合策略，該策略需結合生產平台的多樣性、供應鏈的韌性以及跨通路和區域的精準合作。細胞培養和重組生產技術的進步拓寬了營運選擇，並有助於快速適應抗原變異，而劑型和管道偏好則決定了在醫療機構部署的實際需求。關稅和海關趨勢引入了更多營運變量，各組織必須透過採購柔軟性和合約保障措施來應對這些變量。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：H1N1疫苗市場：依產品類型分類

  • 去活化疫苗
    • 細胞培養類型
    • 蛋製品
    • 重組
  • 減毒活病毒疫苗

第9章：H1N1疫苗市場：依技術分類

  • 細胞培養方法
  • 蛋製品
  • 重組

第10章：H1N1疫苗市場：以劑型分類

  • 多管瓶小瓶
  • 預填充式注射器

第11章：H1N1疫苗市場：依年齡層別分類

  • 成人
  • 兒童
  • 老年人

第12章：H1N1疫苗市場：依最終用戶分類

  • 診所
  • 醫院
  • 公共衛生中心

第13章：H1N1疫苗市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章：H1N1疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：H1N1疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：H1N1疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國H1N1疫苗市場

第18章：中國H1N1疫苗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Biological E. Limited
  • BioNTech SE
  • Blue Lake Biotechnology
  • Capricor Therapeutics, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CSL Limited
  • CureVac NV
  • Daiichi Sankyo Company, Limited.
  • Gennova Biopharmaceuticals Limited
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-437E9896A50B

The H1N1 Vaccines Market was valued at USD 18.32 billion in 2025 and is projected to grow to USD 24.96 billion in 2026, with a CAGR of 36.56%, reaching USD 162.32 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.32 billion
Estimated Year [2026] USD 24.96 billion
Forecast Year [2032] USD 162.32 billion
CAGR (%) 36.56%

Framing the contemporary H1N1 vaccine environment through clinical, manufacturing, regulatory, and distribution lenses for strategic decision-making

The present executive summary distills the critical strategic, operational, and regulatory dimensions shaping the H1N1 vaccine landscape today. Vaccination programs, manufacturing platforms, and procurement policies intersect with evolving public health priorities and technological advances, creating a complex environment in which manufacturers, health systems, and distribution partners must coordinate closely. This summary frames core themes that decision-makers should weigh when aligning R&D investments, supply chain resilience, and commercial strategies with the realities of global immunization campaigns.

Clinical considerations remain central: immunogenicity, safety profiles, dosing formats, and age-specific efficacy influence product selection at the policy level and acceptance among clinicians and the public. Concurrently, manufacturing choices-whether cell-based, egg-based, or recombinant-affect lead times, throughput, and adaptability to antigenic drift. These technical variables have direct implications for procurement cycles, regulatory filing strategies, and the design of collaborative manufacturing arrangements.

Public health imperatives continue to drive demand for dependable vaccine supply and equitable distribution. Effective coordination between manufacturers, hospital systems, clinics, and public health centers is necessary to translate vaccine availability into population-level protection. In this context, the interplay between distribution channels and dosage formats shapes on-the-ground logistics, cold-chain requirements, and administration workflows. The following sections unpack transformative shifts, tariff impacts, segmentation and regional insights, competitive positioning, and actionable recommendations to help stakeholders navigate near-term operational choices and longer-term strategic investments.

Identifying the profound structural changes reshaping H1N1 vaccine development, production, and distribution driven by innovation and operational resilience

The H1N1 vaccine landscape is undergoing transformative shifts driven by platform innovation, supply-chain modernization, and changing stakeholder expectations. Advances in recombinant antigen production and cell-based manufacturing are altering timelines for strain updates and enabling more flexible capacity planning, thereby challenging legacy egg-based paradigms. Concurrently, digitalization in cold-chain monitoring, order management, and inventory forecasting is improving the predictability of distribution while raising expectations for transparency across the value chain.

Market participants are responding to heightened demand for differentiated dosage forms, including pre-filled syringes that simplify administration and multi-dose vials that optimize storage efficiency for mass immunization campaigns. This push-pull dynamic between convenience and cost-efficiency is prompting manufacturers to broaden portfolio strategies and to consider contract manufacturing or fill-finish partnerships to accelerate market readiness. Regulators are increasingly receptive to data packages that demonstrate platform comparability rather than relying on historical pathways, which is expediting the introduction of novel manufacturing approaches while maintaining safety and efficacy standards.

At the same time, public health agencies and procurement bodies are emphasizing resilience: dual sourcing, strategic stockpiles, and geographic diversification of manufacturing footprints have moved from optional best practices to operational imperatives. These shifts are reframing commercial negotiations and partnership models, as buyers seek greater assurances of supply continuity and suppliers focus on operational flexibility to meet variable demand profiles. The result is a more collaborative ecosystem in which data-driven planning, cross-sector partnerships, and investment in adaptable manufacturing platforms determine competitive positioning.

Analyzing how tariff policy in the United States will alter sourcing economics, supply chain design, and procurement complexity for H1N1 vaccine stakeholders

U.S. tariff dynamics in 2025 carry material implications for the H1N1 vaccine ecosystem by influencing input costs, supplier selection, and cross-border manufacturing strategies. Tariff measures that raise the landed cost of imported components-ranging from specialized reagents and single-use bioprocessing consumables to packaging materials and certain finished goods-directly affect manufacturing economics. These cost pressures incentivize manufacturers to reassess sourcing strategies, potentially favoring domestic suppliers or nearshoring options where regulatory and quality frameworks are compatible. In turn, such shifts can alter lead times and introduce transitional complexity as supply chains are revalidated.

Procurement and contracting teams within health systems and public agencies experience the downstream effects of tariff-induced cost variability. Even when tariff policy includes exemptions for certain medical goods or critical inputs, administrative burdens associated with tariff classification, customs documentation, and compliance audits increase transactional friction. This friction can slow order fulfillment, complicate just-in-time inventory strategies, and encourage buyers to prioritize suppliers with integrated global supply chain capabilities that manage customs risk proactively.

Manufacturers respond by redesigning sourcing footprints and negotiating longer-term supply agreements that incorporate tariff contingencies. Firms with diverse platform capabilities-cell-based, egg-based, and recombinant-can adapt manufacturing allocations to mitigate localized cost exposures. Meanwhile, contract manufacturers and distributors that invest in customs expertise and flexible logistics solutions become preferred partners because they reduce the operational risk arising from tariff volatility. Policymakers and industry leaders should therefore treat tariff policy as an operational variable: planning must integrate customs risk assessment, scenario-based procurement terms, and investment in supply chain transparency tools to preserve predictable vaccine availability and maintain cost-effective manufacturing pathways.

Uncovering nuanced segmentation-driven imperatives across product types, technologies, end users, channels, dosage forms, and age cohorts that shape strategy

Segment-level dynamics reveal differentiated commercial and operational priorities that should inform portfolio and channel strategies. Based on Product Type, the market is studied across Inactivated Vaccine and Live Attenuated Vaccine. The Inactivated Vaccine is further studied across Cell Based, Egg Based, and Recombinant. The Live Attenuated Vaccine is further studied across Egg Based. These product distinctions influence manufacturing timelines, regulatory dossiers, and clinician preferences, with cell-based and recombinant inactivated vaccines offering adaptation advantages and egg-based live attenuated formats retaining utility for specific programmatic uses.

Based on Technology, the market is studied across Cell Based, Egg Based, and Recombinant. Technology choice drives capital expenditure profiles, facility design, and skilled workforce requirements, and it shapes the agility with which manufacturers can respond to strain changes. Based on End User, the market is studied across Clinics, Hospitals, and Public Health Centers. End-user segmentation highlights differences in purchase cadence, cold-chain handling capabilities, and clinical administration workflows, which in turn inform packaging and dosage format decisions.

Based on Distribution Channel, the market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. Channel economics and regulatory constraints vary significantly, prompting manufacturers and distributors to tailor distribution agreements and commercial support models to each channel's operational realities. Based on Dosage Form, the market is studied across Multi-Dose Vials and Pre-Filled Syringes. Dosage form choices impact wastage rates, on-site administration speed, and inventory management policies. Based on Age Group, the market is studied across Adults, Children, and Seniors. Age-segmented clinical considerations affect labeling, recommended dosing schedules, and communication strategies directed at caregivers and clinicians. Synthesizing these segmentation layers reveals where investment in platform flexibility, tailored packaging, and targeted stakeholder engagement can deliver the greatest near-term and mid-term returns.

Evaluating how regional regulatory, manufacturing, and procurement differences across the Americas, EMEA, and Asia-Pacific dictate operational strategies and partnerships

Regional dynamics create distinct operational conditions and policy environments that influence manufacturing allocation, distribution design, and regulatory engagement. The Americas encompass a diverse mix of advanced manufacturing capacity, centralized procurement programs, and mature public health infrastructures, which support rapid uptake of new vaccine formats but also require robust commercial evidence packages to secure formulary positions. Europe, Middle East & Africa combines highly regulated markets with variable procurement sophistication and evolving local manufacturing ambitions, requiring adaptive regulatory strategies and flexible supply models to serve both high-capacity health systems and resource-constrained settings.

Asia-Pacific presents a heterogeneous landscape characterized by large population centers with rapidly expanding immunization programs, an increasing number of local manufacturing entrants, and a strong emphasis on cost-containment measures. Regional actors prioritize scalability and price efficiency while simultaneously seeking technology transfer partnerships and local fill-finish capacity to reduce dependence on distant supply chains. The geographic mix of regulatory timelines, logistical realities, and procurement architectures means that manufacturers must tailor regulatory submission strategies, commercial contracting terms, and distribution partnerships to local contexts to achieve operational reliability and policy alignment.

Across these regions, differences in cold-chain infrastructure, public procurement cycles, and local manufacturing incentives determine the optimal balance between centrally produced vaccine lots and regionally manufactured fill-finish operations. Strategic regional planning that integrates regulatory intelligence, logistics capability assessments, and stakeholder engagement plans will reduce time-to-deployment risk and enhance alignment with national immunization program priorities.

Profiling company-level strengths and strategic capabilities that determine supply reliability, regulatory agility, and competitive differentiation in H1N1 vaccines

Competitive positioning in the H1N1 vaccine space reflects a combination of platform capability, manufacturing scale, regulatory relationships, and partnership networks. Leading players demonstrate strength by maintaining multi-platform portfolios that include cell-based and recombinant technologies alongside legacy egg-based production, enabling them to allocate production where it is most efficient and to mitigate supply interruptions. Firms that invest in fill-finish capacity and third-party partnerships reduce bottlenecks and better serve diverse distribution channels and dosage form preferences.

Operational excellence-measured by validated quality systems, robust supply assurance processes, and rapid regulatory responsiveness-differentiates companies when procurement bodies evaluate supplier reliability. Strategic alliances with clinical networks, public health agencies, and international procurement entities enhance product uptake and support lifecycle management activities such as post-market surveillance and age-group specific labeling. Companies that integrate data analytics into demand planning and cold-chain monitoring deliver superior fulfillment performance and reduce wastage, strengthening their commercial propositions to hospitals, clinics, and public health centers.

Innovation pipelines that emphasize antigen design, improved adjuvantation where appropriate, and user-friendly dosage forms position companies to capture segments that prioritize ease of administration and improved patient adherence. At the same time, organizations that invest in regulatory intelligence and cross-border compliance expertise shorten market entry timelines in multiple regions, creating a competitive advantage when rapid response to H1N1 strain shifts is required. For stakeholders assessing partnerships or supplier selection, the combination of technology breadth, manufacturing resilience, and demonstrated execution in distribution channels constitutes a meaningful framework for comparison.

Practical and prioritized strategic measures that manufacturers, distributors, and public health partners can deploy to enhance resilience and accelerate adoption

Industry leaders should prioritize a set of actionable moves that align technical capacity with market and public health needs. First, expand platform flexibility by investing in or partnering for cell-based and recombinant capabilities while preserving targeted egg-based capacity where clinically indicated. This approach increases adaptability to antigenic changes and reduces single-technology exposure. Second, formalize supply assurances through multi-sourcing arrangements and contractual clauses that address customs and tariff variability, thereby protecting procurement commitments and minimizing fulfillment disruptions.

Third, optimize dosage form portfolios to match channel and end-user requirements: prioritize pre-filled syringes for settings where administration speed and patient convenience are paramount, and preserve multi-dose vial options for large-scale immunization programs that prioritize storage efficiency. Fourth, strengthen distribution partnerships by embedding digital cold-chain monitoring and collaborative inventory planning tools that reduce wastage and improve transparency for hospitals, clinics, and public health centers. Invest in training and technical support programs to ensure smooth on-the-ground implementation.

Fifth, engage proactively with regulators and procurement bodies to streamline dossier submissions and to secure predictable procurement pathways. Where tariff exposures exist, pursue advocacy for tariff exemptions or harmonized classifications for critical inputs and finished vaccines. Finally, tailor regional strategies to local regulatory and procurement contexts, leveraging partnerships for local fill-finish or technology transfer where appropriate. Taken together, these steps enhance resilience, create commercial differentiation, and support sustained public health impact.

Explaining the multi-source methodology combining stakeholder interviews, regulatory review, and cross-disciplinary validation to ensure practical and reliable insights

The research methodology underpinning this analysis integrates a combination of primary stakeholder engagement, secondary literature synthesis, and cross-functional subject-matter validation to ensure robust, actionable insights. Primary inputs included structured interviews with manufacturing leaders, regulatory experts, procurement officials, and distribution managers to capture operational realities across manufacturing platforms and distribution channels. These interviews focused on production constraints, regulatory pathways, channel-specific administration dynamics, and procurement considerations relevant to clinics, hospitals, and public health centers.

Secondary analysis encompassed an extensive review of technical regulatory guidance, peer-reviewed clinical literature on vaccine platforms, and operational case studies covering fill-finish logistics and cold-chain practices. Cross-validation workshops with experts in manufacturing scale-up and supply chain risk management were used to reconcile divergent views and to test the feasibility of recommended interventions. Where possible, triangulation between qualitative inputs and publicly available regulatory notices or procurement program descriptions was applied to ensure factual consistency.

Findings were synthesized through a segmentation lens that examined product type, technology, end user, distribution channel, dosage form, and age group implications. Regional intelligence was developed by mapping regulatory pathways, manufacturing capacity, and procurement architectures across the Americas, Europe, Middle East & Africa, and Asia-Pacific. This methodological approach emphasizes practical utility for decision-makers by prioritizing operational levers and contextualized strategies rather than speculative scenarios.

Distilling strategic imperatives and operational priorities that collectively enhance readiness, reliability, and public health impact for H1N1 vaccine programs

In summary, the contemporary H1N1 vaccine environment requires integrated strategies that combine platform diversity, supply-chain resilience, and targeted engagement across channels and regions. Technological progress in cell-based and recombinant manufacturing expands operational options and supports faster adaptation to antigenic change, while dosage form and channel preferences dictate the practicalities of deployment at the point of care. Tariff and customs dynamics introduce an additional operational variable that organizations must manage through sourcing flexibility and contractual safeguards.

Competitive advantage accrues to organizations that harmonize technical capability with executional excellence: demonstrated manufacturing quality, established distribution partnerships, and regulatory agility. Region-specific approaches that account for differences in procurement architectures, regulatory timelines, and infrastructure capacity will reduce deployment friction and enhance alignment with national immunization priorities. By executing on the recommended actions-platform investment, supply assurances, dosage form optimization, digital distribution enablement, and proactive regulatory engagement-stakeholders can improve reliability of supply and responsiveness to public health needs.

The insights presented here are intended to inform near-term operational priorities and medium-term strategic planning without presuming a single pathway for all organizations. Decision-makers should use this synthesis to identify the most actionable levers within their influence, align cross-functional teams, and engage relevant external partners to convert strategic intent into operational reality.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. H1N1 Vaccines Market, by Product Type

  • 8.1. Inactivated Vaccine
    • 8.1.1. Cell Based
    • 8.1.2. Egg Based
    • 8.1.3. Recombinant
  • 8.2. Live Attenuated Vaccine

9. H1N1 Vaccines Market, by Technology

  • 9.1. Cell Based
  • 9.2. Egg Based
  • 9.3. Recombinant

10. H1N1 Vaccines Market, by Dosage Form

  • 10.1. Multi-Dose Vials
  • 10.2. Pre-Filled Syringes

11. H1N1 Vaccines Market, by Age Group

  • 11.1. Adults
  • 11.2. Children
  • 11.3. Seniors

12. H1N1 Vaccines Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Public Health Centers

13. H1N1 Vaccines Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. H1N1 Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. H1N1 Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. H1N1 Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States H1N1 Vaccines Market

18. China H1N1 Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Astellas Pharma Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Bavarian Nordic A/S
  • 19.9. Bharat Biotech Ltd.
  • 19.10. Biological E. Limited
  • 19.11. BioNTech SE
  • 19.12. Blue Lake Biotechnology
  • 19.13. Capricor Therapeutics, Inc.
  • 19.14. Chongqing Zhifei Biological Products Co., Ltd.
  • 19.15. CSL Limited
  • 19.16. CureVac N.V.
  • 19.17. Daiichi Sankyo Company, Limited.
  • 19.18. Gennova Biopharmaceuticals Limited
  • 19.19. GlaxoSmithKline PLC
  • 19.20. Haffkine Bio-Pharmaceutical Corporation Ltd.
  • 19.21. Incepta Pharmaceuticals Ltd.
  • 19.22. Inovio Pharmaceuticals, Inc.
  • 19.23. Johnson & Johnson Services, Inc.
  • 19.24. Merck & Co., Inc.
  • 19.25. Moderna, Inc.
  • 19.26. Novavax, Inc.
  • 19.27. Pfizer Inc.
  • 19.28. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL H1N1 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL H1N1 VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL H1N1 VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL H1N1 VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES H1N1 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA H1N1 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL H1N1 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL H1N1 VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL H1N1 VACCINES MARKET SIZE, BY CELL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL H1N1 VACCINES MARKET SIZE, BY EGG BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL H1N1 VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL H1N1 VACCINES MARKET SIZE, BY MULTI-DOSE VIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL H1N1 VACCINES MARKET SIZE, BY MULTI-DOSE VIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL H1N1 VACCINES MARKET SIZE, BY MULTI-DOSE VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRE-FILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL H1N1 VACCINES MARKET SIZE, BY PRE-FILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL H1N1 VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL H1N1 VACCINES MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL H1N1 VACCINES MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL H1N1 VACCINES MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL H1N1 VACCINES MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL H1N1 VACCINES MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL H1N1 VACCINES MARKET SIZE, BY SENIORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL H1N1 VACCINES MARKET SIZE, BY SENIORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL H1N1 VACCINES MARKET SIZE, BY SENIORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL H1N1 VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL H1N1 VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL H1N1 VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL H1N1 VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL H1N1 VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL H1N1 VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS H1N1 VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL H1N1 VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 145. GCC H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GCC H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 169. G7 H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. G7 H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 177. NATO H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. NATO H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. NATO H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES H1N1 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA H1N1 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA H1N1 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA H1N1 VACCINES MARKET SIZE, BY INACTIVATED VACCINE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA H1N1 VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA H1N1 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)